Vertex Stuck Between A Good Place And A Better Place
Two three-drug regimens for cystic fibrosis hit their primary endpoints in both heterozygous and homozygous patients, with good safety and tolerability, which analysts say increases the likelihood one of them will obtain approval.
You may also be interested in...
Yumanity goes public by merging with Proteostasis; it is accelerating its Parkinson’s program because of mouse model data showing disease-modifying potential. Proteostasis will out-license its CF assets.
Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.
The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.